FDA Approves Sarecycline for Moderate to Severe Acne FDA Approves Sarecycline for Moderate to Severe Acne

The FDA has approved sarecycline (Seysara, Almirall) for patients aged 9 years and older with inflammatory lesions associated with non-nodular moderate to severe acne vulgaris.FDA Approvals

Source: Medscape Medical News Headlines - October 2, 2018 Category: Consumer Health News Tags: Dermatology News Alert Source Type: news